PARP Inhibitor

What PARP Inhibitors Are and How They Work

PARP inhibitors are medicines designed to block an enzyme called PARP (poly ADP-ribose polymerase) inside cells. PARP’s normal job is to help repair damaged DNA, which is the genetic material that tells cells how to grow and function. DNA damage can happen naturally or from things like sunlight, radiation, or some cancer treatments. When PARP is blocked, cells can’t fix certain types of DNA damage as easily.

Cancer cells often have more DNA damage than normal cells and rely heavily on PARP to survive. By stopping PARP, these drugs make it harder for cancer cells to repair themselves, which can lead to their death. This targeted approach aims to attack cancer cells while causing less harm to normal cells.

Why PARP Inhibitors Matter in Cancer Care

PARP inhibitors are especially important for treating cancers that have specific genetic changes, such as mutations in the BRCA1 or BRCA2 genes. These mutations affect how cancer cells repair DNA, making them more dependent on PARP. Blocking PARP in these cancers can be more effective because the cancer cells lose their main way to fix DNA damage.

Doctors may use PARP inhibitors alone or with other treatments like chemotherapy or hormone therapy, depending on the type of cancer and the patient’s situation. These drugs are approved for some ovarian, breast, prostate, and pancreatic cancers and are being studied for others.

What Patients Might Hear or See About PARP Inhibitors

Patients may hear terms like olaparib (brand name Lynparza), rucaparib (Rubraca), or veliparib (ABT-888) when discussing PARP inhibitors. These are examples of drugs in this group. The term might come up during conversations about genetic testing, treatment options, or clinical trials. It’s common to see PARP inhibitors mentioned in treatment plans, drug information sheets, or research studies.

Because these drugs target specific weaknesses in cancer cells, doctors often recommend genetic testing to see if a patient’s cancer might respond well to PARP inhibitors.

What PARP Inhibitors Do Not Automatically Mean

Hearing about PARP inhibitors does not mean a patient will definitely receive this treatment or that it will cure the cancer. Not all cancers respond to these drugs, and their use depends on many factors like genetic test results, cancer type, and previous treatments.

PARP inhibitors are different from traditional chemotherapy and other targeted therapies because they focus on blocking DNA repair. However, they are one option among many, and doctors consider the whole picture before recommending them.

Questions to Ask Your Care Team

If PARP inhibitors are mentioned as part of your care, it can help to ask your healthcare providers why they might be recommended, how they work for your specific cancer, and what side effects to expect. You might also ask if there are clinical trials involving PARP inhibitors that you could join.

Understanding how these drugs fit into your overall treatment plan can help you feel more confident and involved in your care decisions.

Important Notes About This Information

This explanation is meant to help patients and caregivers understand PARP inhibitors but does not replace personalized medical advice. Treatment decisions depend on many individual factors, and only your healthcare team can determine what is best for you.

Next Steps for Patients and Caregivers

If you want to learn more about PARP inhibitors or whether they might be part of your treatment, talk openly with your doctors and nurses. They can explain how these drugs work, whether genetic testing is needed, and what to expect during treatment. Being informed helps you take an active role in your cancer care.